Search results
GoMechanic achieves operational profit in Q1FY25; FY24 revenue at Rs 210 cr
Business Standard India· 14 hours agoCar services and repair platform GoMechanic, which was on the verge of collapse about a...
Pharma sector likely to report 8-10% revenue growth led by domestic business - CNBC TV18
CNBC TV18· 17 hours agoPharmaceutical companies are expected to kick off FY25 with around 8-10% growth in revenue led by...
Pharma and healthcare sector seals $4.1 bn deals in Q2 2024: Report
Business Standard India· 18 hours agoHealthcare funding India Q2: The average deal size also saw a jump, rising from $9.7 million in Q1...
Roche’s foray into continuous glucose monitors dependent on AI efficacy: GlobalData
Financial Express· 19 hours agoGlobalData, a data and analytics company, on Tuesday said that Roche’s artificial intelligence...
Mankind Pharma inks pact with Takeda to commercialise acidity drug in India
Business Standard India· 19 hours agoThe agreement allows Mankind Pharma to launch the novel drug for treating Gastroesophageal Reflux...
COPD one of the fastest growing respiratory diseases in India, study reveals
Financial Express· 19 hours agoA new study has revealed that respiratory diseases are increasing in India. MSRC & Group (Medclin...
Mankind Pharma inks pact with Takeda to commercialise Vonoprazan in India - ET HealthWorld | Pharma
The Economic Times· 19 hours agoThe pharma company has signed a Non-Exclusive Patent License Agreement with Takeda Pharmaceuticals...
Stock market update: Nifty Pharma index falls 0.38%
The Economic Times· 20 hours agoThe Nifty Pharma index closed 0.38 per cent down at 20765.45.
Mankind Pharma signs agreement with Takeda to commercialise novel drug for GERD treatment in India
Financial Express· 22 hours agoVonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related...
Stock market update: Nifty Pharma index advances 0.09% in an upbeat market
The Economic Times· 1 day agoThe Nifty Pharma index was trading 0.09 per cent up at 20862.7.